Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.

Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells. 

Type
Public
HQ
Berkeley, US
Founded
1996
Size (employees)
251 (est)
Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, US
Report incorrect company information

Dynavax Technologies Corporation Office Locations

Dynavax Technologies Corporation has an office in Berkeley
Berkeley, US (HQ)
100 2929 Seventh Street
Show all (1)
Report incorrect company information

Dynavax Technologies Corporation Financials and Metrics

Dynavax Technologies Corporation Financials

Dynavax Technologies Corporation's revenue was reported to be $327 k in FY, 2017
USD

Revenue (FY, 2017)

327 k

Net income (FY, 2017)

(95.2 m)

EBIT (FY, 2017)

(96 m)

Market capitalization (20-Apr-2018)

950.7 m

Cash (31-Dec-2017)

26.6 m
Dynavax Technologies Corporation's current market capitalization is $950.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.3 m11 m4.1 m11 m327 k

Revenue growth, %

(2%)(63%)173%

General and administrative expense

25.9 m17.4 m22.2 m37.3 m27.4 m

R&D expense

50.9 m84.6 m86.9 m84.5 m65 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

3.5 m3 m2.2 m627 k1.6 m1.2 m942 k2.6 m162 k148 k105 k

General and administrative expense

5.8 m4.2 m4.1 m4.1 m4.9 m5.1 m5.5 m8.2 m9.2 m11.8 m6.5 m5.6 m

R&D expense

11.8 m13.2 m23.6 m28.1 m22.2 m19.7 m24.1 m20.1 m22.8 m23.2 m16.3 m14.8 m

Operating expense total

18.5 m17.5 m27.9 m32.3 m27.1 m24.8 m29.6 m28.2 m31.9 m35 m25.6 m20.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

23.1 m49.5 m44.8 m24.3 m26.6 m

Accounts Receivable

1.6 m727 k1.4 m

Inventories

1.4 m4.1 m2.4 m6.8 m312 k

Current Assets

192.4 m127.4 m199.9 m89.6 m198 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

12.2 m26.8 m17 m19.7 m14.7 m36.5 m103 m38.9 m24.8 m23 m21.5 m37.7 m

Accounts Receivable

2.2 m1.7 m1.3 m727 k909 k657 k1.2 m1.2 m

Current Assets

79.8 m181.7 m160.6 m134.9 m102 m97.9 m224.3 m170.7 m147.1 m117.5 m89.7 m132.2 m

PP&E

8.5 m8.6 m8.8 m8.1 m7.5 m8.9 m11.6 m15.9 m17.4 m18.7 m16.6 m16.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)(95.2 m)

Depreciation and Amortization

1.3 m1.4 m1.4 m2.3 m3.2 m

Inventories

677 k(2.7 m)1.6 m560 k(312 k)

Accounts Payable

(657 k)(523 k)1.2 m1.2 m(1.9 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.7 m)(13.8 m)(24.8 m)(29.8 m)(26.2 m)(23.6 m)(30.1 m)(27 m)(29 m)(34.7 m)(25.3 m)

Accounts Payable

1.9 m5 m3.3 m2.3 m2.4 m3.5 m4.5 m3.8 m1.5 m
USDY, 2017

Revenue/Employee

1.3 k

Financial Leverage

1.1 x
Show all financial metrics

Dynavax Technologies Corporation Operating Metrics

FY, 2016

Patents (foreign)

260

Patents Pending

40

Phase III Trials Products

1

Preclinical Phase Products

2
Show all operating metrics
Report incorrect company information